(Q34292532)

English

Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Marie-Françoise Chesselet

10

object named as

Marie-Françoise Chesselet

1 reference

Europe PubMed Central

1 August 2017

author name string

Iddo Magen

1

1 reference

Europe PubMed Central

1 August 2017

Regina Ostritsky

2

1 reference

Europe PubMed Central

1 August 2017

Franziska Richter

3

1 reference

Europe PubMed Central

1 August 2017

Chunni Zhu

4

1 reference

Europe PubMed Central

1 August 2017

Sheila M Fleming

5

1 reference

Europe PubMed Central

1 August 2017

Vincent Lemesre

6

1 reference

Europe PubMed Central

1 August 2017

Alistair J Stewart

7

1 reference

Europe PubMed Central

1 August 2017

Bruce H Morimoto

8

1 reference

Europe PubMed Central

1 August 2017

Illana Gozes

9

1 reference

Europe PubMed Central

1 August 2017

publication date

6 August 2014

1 reference

Europe PubMed Central

1 August 2017

Pharmacology Research & Perspectives

1 reference

Europe PubMed Central

1 August 2017

2

1 reference

Europe PubMed Central

1 August 2017

5

1 reference

Europe PubMed Central

1 August 2017

e00065

1 reference

Europe PubMed Central

1 August 2017

describes a project that uses

1 reference

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4186425/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Autophagy has a key role in the pathophysiology of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

A clinical approach towards smell loss in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Decreased bacterial adherence and biofilm growth on surfaces coated with a solution of benzalkonium chloride.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Modelling of Parkinson's disease in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Genome-wide association study reveals genetic risk underlying Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Olfactory deficits in mice overexpressing human wildtype alpha-synuclein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Statistical data analysis in the computer age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Peptide neuroprotection through specific interaction with brain tubulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

6 July 2018

Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186425

28 October 2018

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1002%2FPRP2.65

21 January 2018

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

1 reference

https://pubmed.ncbi.nlm.nih.gov/25505609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PRP2.65

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34292532&oldid=1955206820"